Search Results

You are looking at 131 - 140 of 526 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag, and Tanios Bekaii-Saab

the question as to the utility of the current standard of care, which is 6 months of perioperative systemic therapy. Given the unclear utility of adjuvant therapy after preoperative therapy has been administered, the clinical importance of pathologic

Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

dissection for melanoma . J Clin Oncol 2004 ; 22 : 3677 – 3684 . 70 Cascinelli N Belli F MacKie RM . Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised

Full access

A Change of Heart

Crystal S. Denlinger

as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer . J Clin Oncol 2012 ; 30 : 3792 – 3799 . 5. Bonneterre J Roché H Kerbrat P . Long-term cardiac follow-up in relapse

Full access

Ten Years of Progress in Non–Small Cell Lung Cancer

David S. Ettinger

fusion gene EML-4 ALK . This mutation seems to be mutually exclusive with the EGFR and KRAS mutation in the phase I study. Adjuvant Therapy In 2004, the International Adjuvant Lung Cancer Trial showed an approximately 5% survival advantage

Full access

Taxanes in the Adjuvant Treatment of Breast Cancer

Donna Trauth and Lori J. Goldstein

1998 ; 17 : 101 . 65 Eifel P Axelson JA Costa J . National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3 2000 . J Natl Cancer Inst 2001 ; 93 : 979 . www

Full access

Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data

Ali Raza Khaki, V.K. Gadi, and Vinay Prasad

LA , Davis GJ , . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980 – 991 . 11181660 10.1200/JCO.2001.19.4.980 2. Wishart GC , Azzato EM , Greenberg

Full access

Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review

Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea

should be tempered by maximal preservation of neurologic function. What does seem to be apparent is that STR without any adjuvant therapy is associated with a poor prognosis. There have been 16 cases presented in the literature that have undergone STR or

Full access

Risk Stratification and Selection of Management Strategy for Localized Prostate Cancer

Presented by: Alice Yu

involves deciding whether a patient should receive adjuvant therapy after prostatectomy. The GC score was retrospectively validated in a postprostatectomy cohort. 12 In a retrospective dataset of >300 patients who underwent radical prostatectomy without

Full access

Molecular Profiling in Cutaneous Melanoma

Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter

predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate

Full access

Differences in Medicare Expenditures Between Appalachian and Nationally Representative Cohorts of Elderly Women With Breast Cancer: An Application of Decomposition Technique

Ami Vyas, S. Suresh Madhavan, and Usha Sambamoorthi

months) after BC diagnosis constituted 37% of BC Medicare spending, which is substantially higher due to surgery and adjuvant therapy. 2 – 6 Additionally, elderly women aged ≥65 years have higher BC incidence compared with their younger counterparts, 7